PET and MRI Imaging of Brain Tumors Using [18F]PARPi

Early Phase 1

Active, not recruiting

• Conditions: Brain Cancer; Brain Tumor
• Interventions: Diagnostic Test: PET/MR with [18F]PARPi; Drug: [18F]PARPi

• Registration Number: NCT04173104
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

This study is to collect data about how 18FPARPi can be used together with PET/positron emission tomography and MRI/magnetic resonance imaging scans to take pictures of brain cancer

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2019-11-01
• Study First Submitted: 2019-11-19
• Study First Submitted QC: 2019-11-20
• Study First Posted: 2019-11-21
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-13
• Last Update Posted: 2024-12-18
• Primary Completion: 2025-11
• Study Completion: 2025-11

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

• Patients with new or suspected recurrent brain tumors (including suspected recurrent brain tumors showing growth from any preceding scan)
• Age >/= 18 years
• Minimum at least one brain lesion size >/= 1.5cm diameter
• Scheduled to undergo treatment at MSK
• Willingness to sign informed consent
• Able to receive intravenous gadolinium contrast per MSK Department of Radiology guidelines

Read More

Exclusion Criteria

• Any contraindication to 3T MRI (PET/MR scanner is 4.0 Tesla)
• Pregnancy or breast-feeding women

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Participants with Brain Cancer	PET/MR with [18F]PARPi	Participants with new or suspected recurrent brain tumors
Participants with Brain Cancer	[18F]PARPi	Participants with new or suspected recurrent brain tumors

Primary Outcome Measures

Name	Time	Method
SUVmax measurements	Up to 24 weeks	\[18F\]PARPi updtake in lesions will be quantified by standard SUVmax measurements from PET/MR scans

Trial Locations

Locations (1)

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States